In short
Tazemetostat is an emerging drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the use of tazemetostat in clinical trials, focusing on its applications, efficacy, and safety profile across multiple cancer types.
At a glance
- Drug Name
- Tazemetostat (also known as EPZ-6438, E7438)
- Mechanism of Action
- Selective small molecule inhibitor of EZH2 (enhancer of zeste homolog 2)
- Cancer Types Studied
- B-cell lymphomas (follicular lymphoma, diffuse large B-cell lymphoma), solid tumors, epithelioid sarcoma, synovial sarcoma, malignant mesothelioma
- Administration
- Oral tablets, typically 800 mg twice daily in 28-day cycles
- Primary Outcomes
- Objective response rate (ORR), progression-free survival (PFS), safety and tolerability, pharmacokinetic parameters
- Notable Trials
- NCT01897571, NCT02875548, NCT02860286, NCT03009344
- Safety Considerations
- Monitored for adverse events, specific concerns vary by cancer type and patient population
- Potential Biomarkers
- EZH2 mutations, BAP1 loss of function (in mesothelioma)
What is Tazemetostat?
Tazemetostat is a medication used in the treatment of various types of cancer. It is also known by other names such as EPZ-6438, E7438, IPN60200, and TAZVERIK. Tazemetostat is a type of drug called a small molecule inhibitor, which means it works by blocking specific processes in cancer cells.
How Does Tazemetostat Work?
Tazemetostat targets a protein in cells called EZH2 (enhancer of zeste homolog 2). EZH2 is an enzyme that plays a role in controlling which genes are active or inactive in cells. In some types of cancer, EZH2 becomes overactive, leading to uncontrolled cell growth. By inhibiting EZH2, tazemetostat aims to slow down or stop the growth of cancer cells.
What Conditions Does Tazemetostat Treat?
Tazemetostat has shown promise in treating several types of cancer, including:
- Follicular Lymphoma (FL): A type of slow-growing blood cancer that affects white blood cells called B-cells.
- Diffuse Large B-cell Lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma that also affects B-cells.
- Epithelioid Sarcoma (ES): A rare type of soft tissue cancer.
- Synovial Sarcoma: Another type of soft tissue cancer that typically occurs near joints.
- Malignant Rhabdoid Tumors: Rare and aggressive cancers that can occur in various parts of the body, especially in children.
- INI1-negative tumors: Cancers that lack a specific protein called INI1, which helps control cell growth.
Tazemetostat is particularly useful for treating cancers that have returned after previous treatment (relapsed) or have not responded well to other treatments (refractory).
Administration and Dosage
Tazemetostat is typically taken orally (by mouth) in the form of tablets. The usual adult dose is 800 mg twice daily, but this can vary depending on the specific condition being treated and the patient's individual needs. For children aged 12-17, the dose may be adjusted based on body surface area (520 mg/m2/dose twice daily). Treatment cycles usually last 28 days and may continue for up to 2 years or until the disease progresses or side effects become unmanageable.
Ongoing Research
Researchers are currently studying tazemetostat's effectiveness in treating other types of cancer, including:
- Solid tumors with ARID1A mutations: ARID1A is a gene that, when mutated, can contribute to cancer growth. Studies are exploring whether tazemetostat can help patients with various solid tumors that have this mutation.
- Malignant Peripheral Nerve Sheath Tumors (MPNST): These are rare cancers that develop in the protective covering of nerves.
- COVID-19-related complications: Interestingly, one study is investigating whether tazemetostat could help treat severe inflammatory reactions in COVID-19 patients.
Potential Side Effects
Like all medications, tazemetostat can cause side effects. Common side effects may include:
- Fatigue
- Nausea
- Decreased appetite
- Changes in blood cell counts
- Muscle and bone pain
Your healthcare team will monitor you closely for any side effects and adjust your treatment if necessary.
Drug Interactions
Tazemetostat can interact with other medications. Specifically:
- Strong CYP3A inhibitors (like itraconazole): These drugs can increase the levels of tazemetostat in your body, potentially increasing side effects.
- Strong CYP3A inducers (like rifampin): These drugs can decrease the levels of tazemetostat in your body, potentially making it less effective.
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.